Lee Tombs

898 total citations
60 papers, 638 citations indexed

About

Lee Tombs is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lee Tombs has authored 60 papers receiving a total of 638 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 32 papers in Physiology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lee Tombs's work include Chronic Obstructive Pulmonary Disease (COPD) Research (47 papers), Asthma and respiratory diseases (32 papers) and Respiratory Support and Mechanisms (22 papers). Lee Tombs is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (47 papers), Asthma and respiratory diseases (32 papers) and Respiratory Support and Mechanisms (22 papers). Lee Tombs collaborates with scholars based in United States, United Kingdom and Canada. Lee Tombs's co-authors include Ian Naya, David A. Lipson, Paul Jones, Dave Singh, William A. Fahy, I. Boucot, Rodger Kempsford, Chris Compton, M. Reza Maleki-Yazdi and Edward Kerwin and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, European Respiratory Journal and Thorax.

In The Last Decade

Lee Tombs

59 papers receiving 630 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lee Tombs United States 14 595 462 25 17 17 60 638
Gonzalo de Miquel Spain 10 371 0.6× 300 0.6× 8 0.3× 31 1.8× 6 0.4× 24 407
Lawrence Korducki United States 13 813 1.4× 697 1.5× 47 1.9× 17 1.0× 2 0.1× 39 841
A.P.M. Greefhorst Netherlands 9 674 1.1× 521 1.1× 24 1.0× 23 1.4× 15 0.9× 10 767
Sophie Demarche Belgium 12 228 0.4× 299 0.6× 10 0.4× 2 0.1× 3 0.2× 18 434
Alison Donald United Kingdom 10 212 0.4× 181 0.4× 9 0.4× 2 0.1× 4 0.2× 20 307
S. Lal United Kingdom 10 167 0.3× 143 0.3× 40 1.6× 10 0.6× 24 1.4× 19 314
Nicola Cassidy Ireland 9 117 0.2× 39 0.1× 12 0.5× 33 1.9× 16 210
Daniel Bech Rasmussen Denmark 9 161 0.3× 52 0.1× 50 2.0× 16 0.9× 29 224
Enrico Mondati Italy 7 108 0.2× 73 0.2× 16 0.6× 10 0.6× 12 246
GL Jensen United States 6 43 0.1× 250 0.5× 31 1.2× 4 0.2× 8 0.5× 6 377

Countries citing papers authored by Lee Tombs

Since Specialization
Citations

This map shows the geographic impact of Lee Tombs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee Tombs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee Tombs more than expected).

Fields of papers citing papers by Lee Tombs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lee Tombs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee Tombs. The network helps show where Lee Tombs may publish in the future.

Co-authorship network of co-authors of Lee Tombs

This figure shows the co-authorship network connecting the top 25 collaborators of Lee Tombs. A scholar is included among the top collaborators of Lee Tombs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lee Tombs. Lee Tombs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aggarwal, Bhumika, Paul Jones, Alejandro Casas, et al.. (2024). Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT Study. Pulmonary Therapy. 10(2). 183–192. 6 indexed citations
2.
3.
Martinez, Fernando J., Gerard J. Criner, Lee Tombs, et al.. (2024). ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD. European Respiratory Journal. 65(2). 2400171–2400171. 3 indexed citations
4.
Halpin, David, Surya P. Bhatt, Marc Miravitlles, et al.. (2024). Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis. PA1173–PA1173. 1 indexed citations
5.
Bjermer, Leif, I. Boucot, Claus Vogelmeier, et al.. (2021). Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy. 38(9). 4815–4835. 4 indexed citations
6.
Vogelmeier, Claus, Paul Jones, Edward Kerwin, et al.. (2021). Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial. Respiratory Research. 22(1). 279–279. 4 indexed citations
7.
Bjermer, Leif, François Maltais, C. Franz Vogelmeier, et al.. (2020). Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed to Treat Analysis of the EMAX Trial. A3326–A3326.
8.
9.
Maltais, François, Ian Naya, Claus Vogelmeier, et al.. (2020). Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial. Respiratory Research. 21(1). 280–280. 10 indexed citations
10.
Naya, Ian, Lee Tombs, David A. Lipson, I. Boucot, & Chris Compton. (2019). Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respiratory Research. 20(1). 60–60. 10 indexed citations
11.
Naya, Ian, Lee Tombs, David A. Lipson, & Chris Compton. (2018). Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis. Advances in Therapy. 35(10). 1626–1638. 11 indexed citations
12.
Riley, John, Chris Kalberg, Alison Donald, et al.. (2018). Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Research. 4(1). 73–2017. 10 indexed citations
13.
Tombs, Lee, Michael J. Asmus, I. Boucot, et al.. (2018). Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials. Drugs & Aging. 35(7). 637–647. 5 indexed citations
14.
Singh, Sally, François Maltais, Lee Tombs, et al.. (2018). Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD. International Journal of COPD. Volume 13. 203–215. 8 indexed citations
15.
Naya, Ian, Lee Tombs, Hana Muellerova, Christopher Compton, & Paul Jones. (2018). Long-term outcomes following first short-term clinically important deterioration in COPD. Respiratory Research. 19(1). 222–222. 29 indexed citations
16.
Maleki-Yazdi, M. Reza, Dave Singh, Antonio Anzueto, et al.. (2016). Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. Advances in Therapy. 33(12). 2188–2199. 37 indexed citations
17.
Singh, Dave, M. Reza Maleki-Yazdi, Lee Tombs, et al.. (2016). Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. International Journal of COPD. Volume 11. 1413–1424. 54 indexed citations
18.
Oliver, Amanda J., et al.. (2014). Tolerability of Fluticasone Furoate/Vilanterol Combination Therapy in Children Aged 5 to 11 Years With Persistent Asthma. Clinical Therapeutics. 36(6). 928–939.e1. 15 indexed citations
19.
Kelleher, Dennis, Lee Tombs, Andrew Preece, Noushin Brealey, & Rashmi Mehta. (2014). A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulmonary Pharmacology & Therapeutics. 29(1). 49–57. 17 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gonzalo de Miquel Breakdown of academic impact, for papers by Lawrence Korducki Breakdown of academic impact, for papers by A.P.M. Greefhorst Breakdown of academic impact, for papers by Sophie Demarche Breakdown of academic impact, for papers by Alison Donald Breakdown of academic impact, for papers by S. Lal Breakdown of academic impact, for papers by Nicola Cassidy Breakdown of academic impact, for papers by Daniel Bech Rasmussen Breakdown of academic impact, for papers by Enrico Mondati Breakdown of academic impact, for papers by GL Jensen
Rankless by CCL
2026